A groundbreaking blood test could identify dementia risk in women up to 25 years before symptoms appear, according to research from the University of California San Diego.
Researchers from the University of California San Diego have developed a blood test that may determine a woman’s risk of developing dementia as early as 25 years before any symptoms manifest. This promising finding centers on a specific biomarker protein associated with the early pathological processes of Alzheimer’s disease, known as phosphorylated tau 217 (p-tau217).
The study analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, conducted in the late 1990s. The participants, aged between 65 and 79, exhibited no signs of cognitive decline at the study’s outset. Over a follow-up period of up to 25 years, researchers found a strong association between elevated levels of p-tau217 and future instances of mild cognitive impairment and dementia.
Women with higher levels of p-tau217 at the beginning of the study were significantly more likely to develop dementia later on. The findings were published in JAMA Network Open, highlighting the potential for early detection of dementia risk through a simple blood test.
“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, the study’s first author and an associate professor of public health and medicine at UC San Diego. “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”
This early detection could pave the way for preventive strategies and targeted monitoring, allowing for interventions before memory issues disrupt daily life. Shadyab emphasized that as research progresses, these biomarkers could help pinpoint individuals at the greatest risk and inform strategies to delay or prevent dementia.
However, the relationship between p-tau217 levels and dementia risk was not uniform across all demographics. The study indicated that women over 70 with elevated p-tau217 levels experienced poorer cognitive outcomes compared to their younger counterparts. Additionally, those with the APOE ε4 gene, a known risk factor for Alzheimer’s disease, also showed a stronger correlation between p-tau217 levels and cognitive decline.
Interestingly, the study revealed that p-tau217 was a more significant predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy, compared to those who received a placebo. This finding suggests that hormonal factors may play a role in the relationship between p-tau217 levels and dementia risk.
Senior author Linda K. McEvoy, a senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, noted the advantages of blood-based biomarkers like p-tau217. “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” she explained. “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”
Despite the promising nature of these findings, Shadyab cautioned that blood tests for Alzheimer’s disease are still under investigation and are not yet recommended for routine screening in asymptomatic individuals. Further research is necessary before this approach can be considered for clinical use prior to the onset of cognitive symptoms.
Future studies should explore how various factors, including genetics, hormone therapy, and age-related medical conditions, may interact with plasma p-tau217 levels. Shadyab also pointed out that the study focused exclusively on older women, indicating that the findings may not be applicable to men or younger populations. Additionally, the research examined overall dementia outcomes rather than specific subtypes, such as Alzheimer’s disease.
As the understanding of dementia risk factors evolves, the potential for early detection through blood tests like p-tau217 may revolutionize the approach to managing and preventing this debilitating condition.
According to Fox News Digital, the implications of this research could significantly impact future dementia prevention strategies.